PT - JOURNAL ARTICLE AU - Zhu, Yuru AU - Gu, Jia AU - Qiu, Yumou AU - Chen, Song Xi TI - Real-World COVID-19 Vaccine Protection Rates against Infection in the Delta and Omicron Eras AID - 10.1101/2022.09.01.22279492 DP - 2022 Jan 01 TA - medRxiv PG - 2022.09.01.22279492 4099 - http://medrxiv.org/content/early/2022/09/02/2022.09.01.22279492.short 4100 - http://medrxiv.org/content/early/2022/09/02/2022.09.01.22279492.full AB - The real-world protection rates of vaccination (VPRs) against the SARS-Cov-2 infection are critical in formulating future vaccination strategies against the virus. Based on a varying co-efficient stochastic epidemic model, we obtain seven countries’ real-world VPRs using daily epidemiological and vaccination data, and find that the VPRs improved with more vaccine doses. The average VPR of the full vaccination was 82% (SE: 4%) and 61% (SE: 3%) in the pre-Delta and Delta-dominated periods, respectively. The Omicron variant reduced the average VPR of the full vaccination to 39% (SE: 2%). However, the booster dose restored the VPR to 63% (SE: 1%) which was significantly above the 50% threshold in the Omicron-dominated period. Scenario analyses show that the existing vaccination strategies have significantly delayed and reduced the timing and the magnitude of the infection peaks, respectively, and doubling the existing booster coverage would lead to 29% fewer confirmed cases and 17% fewer deaths in the seven countries compared to the outcomes at the existing booster taking rates. These call for higher full vaccine and booster coverage for all countries.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by National Natural Science Foundation of China Grants 92046021, 12071013 and 12026607.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available online at "https://covid.ourworldindata.org/".